What you should know
- The financing: Actually has closed a $300 million investment round led by Series X Capital, a venture fund established specifically to scale Google X “moonshot” technologies into independent companies.
- The restructuring: The company has officially transitioned its legal structure from an LLC to a corporation, most recently named Verily Health Inc.
- Alphabet’s new role: In a massive corporate change, Alphabet (Google’s parent company) will remain a “significant minority investor” but will no longer have a majority stake in the company it originally spun off a decade ago.
- The strategic objective: The $300 million will accelerate Verily’s AI-native precision health platform strategy, specifically aimed at helping healthcare organizations harmonize fragmented data and deploy actionable intelligence into clinical workflows.
- The business ecosystem: Verily announced major commercial partnerships, including a collaboration with Samsung (which uses the Galaxy Watch for biomarker development) and Salesforce (which integrates the Verily Pre platform with Agentforce Health).
- Clinical Partners: The round also featured participation from UCHealth and the University of Colorado Anschutz, which are actively using the Verily Pre platform to transform clinical research and care delivery.
The power of independence
Why is it important for Alphabet to give up its controlling stake? Because in corporate healthcare, supplier neutrality is everything. When a health IT company is considered a pure subsidiary of a tech giant, potential partners (and competitors of that parent company) are often hesitant to become deeply integrated. By establishing true corporate independence, Verily Health Inc. has unlocked the ability to freely partner across the medical and technology ecosystem.
We are already seeing this play out in real time. In addition to the funding, Verily announced major commercial partnerships that cross traditional technological fault lines. They are collaborating with Samsung to use the Galaxy Watch for biomarker development in clinical research and have established a strategic partnership with Salesforce to integrate their precision health platform (Verily Pre) directly into Salesforce’s Agentforce Health.
“Today is an important step in our mission to deliver the promise of precision health to everyone,” said Stephen Gillett, president and CEO of Verily. “From research to care, our customers need solutions that combine the best of clinical and scientific rigor with AI to deliver the next generation of healthcare, one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this healthcare transformation.”
Climbing the “Moonshot”
Series X Capital’s presence as a lead investor is also very strategic. Led by former YouTube and Facebook executive Gideon Yu, the fund was explicitly established to act as the “last mile of incubation,” taking the most promising Google X projects and structuring them into financially disciplined and commercially viable independent companies.
With this war chest, Verily is aggressively attacking the most persistent bottleneck in modern medicine: siled, unstructured data. Health systems are drowning in data but hungry for information. Verily’s Pre Native AI platform is designed to ingest this multimodal health data and generate highly personalized predictive models that clinicians can use at the bedside.
“Partnering with Verily to bring a shared data framework to healthcare data, making it AI-ready, creates a generational opportunity for UCHealth and for medicine,” said Dr. Richard Zane, chief medical and innovation officer at UCHealth, who also participated in the funding round.
